A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc

Journal of Acquired Immune Deficiency Syndromes

Volumn 42, Issue 2, 2006, Pages 183-191

  Rosario, Maria C ^a   Poland, Bill ^b   Sullivan, John ^c   Westby, Mike ^d   Van Der Ryst, Elna ^e  

^a PFIZER INC   (United States)

^b PHARSIGHT CORPORATION   (United States)

^c Department of Clinical Statistics ^*  (United Kingdom)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^e Clinical R and D   (United Kingdom)

Author keywords

CCR5 antagonists; Maraviroc; Modeling; MVC; Simulations; UK 427,857; Viral dynamics model

Indexed keywords

MARAVIROC; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MODEL; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; MATHEMATICAL MODEL; MONOTHERAPY; MONTE CARLO METHOD; MULTICENTER STUDY; PARAMETER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPRODUCTION; SCREENING; VIRUS INHIBITION; VIRUS LOAD;

ANTI-HIV AGENTS; COMPUTER SIMULATION; CYCLOHEXANES; DOSE-RESPONSE RELATIONSHIP, DRUG; FOOD; HIV INFECTIONS; HIV-1; HUMANS; MONTE CARLO METHOD; PLACEBOS; RNA, VIRAL; TRIAZOLES; VIRAL LOAD;

EID: 33745077340     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000220021.64115.37     Document Type: Article

References (34)

1. Bonhoeffer S, May RM, Shaw GM, et al. Virus dynamics and drug therapy. Proc Natl Acad Sci U S A. 1997; 94:6971-6976.
2. Bonhoeffer S, Mohri H, Ho DD, et al. Quantification of cell turnover kinetics using 5-bromo-2′-deoxyuridine. J Immunol. 2000;164:5049-5054.
3. Hsu A, Wada DR, Liu M, et al. PK/PD modeling of ABT-378/ritonavir clinical trials, including an adherence factor. Paper presented at: Seventh European Conference on Clinical Aspects and Treatment of HIV-infection; 1999; Lisbon, Portugal.
4. Hurwitz SJ, Schinazi RF. Development of a pharmacodynamic model for HIV treatment with nucleoside reverse transcriptase and protease inhibitors. Antiviral Res. 2002;56(2):115-127.
5. Poland B, Wada R. Combining drug-disease and economic modeling to inform drug development decisions. Drug Discov Today. 2002;6(22):1165-1170.
6. Gieschke R, Fotteler B, Buss N, et al. Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients. Clin Pharmacokinet. 1999;37(1):75-86.
7. Mould DR, Zhang X, Nieforth K, et al. Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients. Clin Pharmacol Ther. 2005;77(6):515-528.
8. Rosario MC, Jacqmin P, Dorr P, et al. A PK-PD-Disease model to support the design of clinical trials of drugs for the treatment of HIV. Paper presented at: 12th PAGE meeting; 12-13 June 2003; Verona, Italy. Available at: http://www.page-meeting.org/. Accessed March 24, 2006.
9. Rosario MC, Jacqmin P, Dorr P, et al. A pharmacokinetic-pharmacodynamic- disease model to predict in vivo antiviral activity of maraviroc. Clin Pharmacol Ther. 2005;78:508-519.
10. Phillips AN. Reduction of HIV concentration during acute infection: independence from a specific immune response. Science. 1996;271:497-499.
11. Funk GA, Fischer M, Joos B, et al. Quantification of in vivo replicative capacity of HIV-1 in different compartments of infected cells. J Acquir Immune Defic Syndr. 2001;26:397-404.
12. Miller R, Ewy W, Corrigan BW, et al. How modeling and simulation have enhanced decision making in new drug development. J Pharmacokinet Pharmacodyn. 2005;32(2):185-197.
13. Richman DD, Wrin T, Little S, et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A. 2003;100:4144-4149.
14. Fatkenheuer G, Pozniak A, Johnson M, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med. 2005;11(11):1170-1172.
15. th Congress on Retrovirus and Opportunistic Infections; 10-14 February, 2003; Boston. Accessed March 24, 2006.
16. NONMEM Users Guides [computer program]. Version V: GloboMax LLC; 1992.
17. Trial simulator [computer program]. Version 2.1.2: Pharsight Corporation.
18. S-Plus [computer program]. Version 6.0 Professional: Insightful Corp; 1988.
19. Rosario MC, Poland B, Felstead S, et al. Modeling of UK-427,857, a novel CCR5 antagonist, efficacy in short-term monotherapy (Abstract TuPeB4479). Paper presented at: XV International AIDS Conference; 11-16 July 2004; Bangkok, Thailand. Available at: http://www.aids2004.org/. Accessed March 24, 2006.
20. Lalezari JP, Thompson M, Kumar P, et al. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. AIDS. 2005;19(14):1443-1448.
21. Lalezari JP, Thompson M, Kumar P, et al. 873140, a novel CCR5 antagonist: antiviral activity and safety during short-term monotherapy in HIV-infected adults. Paper presented at: 44th ICAAC; 30th October-2nd November 2004; Washington, DC.
22. Schuermann D, Pechardscheck C, Rouzier R, et al. Vicriviroc (formerly SCH 417690): antiviral activity of a potent new CCR5 receptor antagonist. Paper presented at: 3rd International AIDS Society conference on HIV pathogenesis and treatment; 24-27 July 2005; Rio de Janeiro. Available at: http://www.thebody. com/confs/ias2005/pdfs/TuOa0205.ppt. Accessed March 24, 2006.
23. Schurmann R, Rouzier R, Nougarede R, et al. SCH D: Antiviral activity of a CCR5 receptor antagonist. Paper presented at: 11th Conference on retroviruses and opportunistic infections; 8-11 February 2004; San Francisco. Available at: http://www.retroconference.org/2004/cd/Abstract/140LBhtm.
24. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995;373:111-122.
25. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123-167.
26. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996;271:1582-1585.
27. Gruzdev B. A randomized double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive HIV-1 infected subjects. AIDS. 2003;17:2487-2494.
28. Louie M, Hogan C, Hurley A, et al. Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. AIDS. 2003;17:1151-1156.
29. Rousseau FS, Kahn JO, Thompson M, et al. Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil). J Antimicrob Chemother. October 1, 2001;48(4):507-513.
30. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1 infected compartments during combination therapy. Nature. 1997;387:188-191.
31. Notermans DW, Goudsmit J, Danner SA, et al. Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen. AIDS. 1998;12:1483-1490.
32. Mittler J, Essunger P, Yuen GJ, et al. Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy. Antimicrob Agents Chemother. May 1, 2001;45(5):1438-1443.
33. Polis MA, Sidorov IA, Yoder C, et al. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. Lancet. 2001;358:1760-1765.
34. Rosario MC, Poland B, Nichols D. PK-PD-Disease model to predict viral load drop from monotherapy with UK-427,857 (Abstract W 4356). Paper presented at: Annual meeting; 2004; Baltimore, MD.